We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 164% below its sector, cheaper than its peers on earnings.
MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific region, and other international markets. MedMira offers a diverse portfolio of rapid diagnostic tests and technology platforms. Its diagnostic solutions include Reveal HIV, which identifies HIV-1 and HIV-2 antibodies in various blood samples; Reveal TP, a rapid test for syphilis antibodies (Treponema pallidum); and Reveal HP, designed to detect Helicobacter pylori antibodies. The company also provides Multiplo, a line of multiplex tests for combined screening of conditions such as HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. In the realm of respiratory and viral diagnostics, MedMira developed VYRA CoV2 for SARS-CoV-2 nucleocapsid antigen detection, VYRA CoV2Flu for simultaneous antigen testing of SARS-CoV-2, Influenza A, and Influenza B, and REVEALCOVID-19, an antibody test for COVID-19. Beyond diagnostic kits, MedMira provides the Miriad RVF toolkit, a platform that facilitates the development and market entry of rapid diagnostics. MedMira distributes its offerings through a wide network of medical distributors and strategic partners. Its customer base is broad, serving various segments of the healthcare industry, including clinical laboratories, hospitals, point-of-care clinics, government agencies, humanitarian aid groups, and public health bodies. The company was established in 1993, is headquartered in Halifax, Canada, and operates as a subsidiary of MedMira Holding AG.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save MIR.V and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
